Bidding war intensifies for Metsera

Another round of bids shows Novo Nordisk remains the higher bidder for obesity play Metsera, while Pfizer is hoping its clearer path to completing a deal gives it leverage.

Metsera Inc. (NASDAQ:MTSR) disclosed on Tuesday that it had received amended acquisition proposals from Pfizer Inc. (NYSE:PFE) and Novo Nordisk A/S (CSE:NOVO-B; NYSE:NVO), with Novo’s offer remaining the “superior company proposal” as defined by Metsera in the context of the existing Pfizer merger agreement...